Hanmi Science (008930.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7008930000

Price
42,400.00 KRW
Market cap
2.87 tn KRW
P/E (2025)
24.25
P/S (2025)
2.12
Dividend yield
0.71 %
Net margin
8.72 %
Return on equity (ROE)
12.31 %
Return on assets (ROA)
7.95 %

Hanmi Science financials

Fiscal year20242025
Revenue1.28 tn KRW1.36 tn KRW
Gross profit272.58 bn KRW315.54 bn KRW
Operating income37.96 bn KRW56.96 bn KRW
EBIT74.44 bn KRW143.57 bn KRW
Net income59.42 bn KRW118.37 bn KRW
Diluted EPS – continuing operations877.54 KRW1,748.09 KRW

Full history since 2000, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Hanmi Science

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.